Recent patents related to phosphorylation signaling pathway on cancer

Recent Patents on DNA and Gene Sequences

Volumn 5, Issue 3, 2011, Pages 175-184

  Acosta, Karina B ^a   Tibolla, María M ^a   Tiscornia, María M ^a   Lorenzati, María A ^a   Zapata, Pedro D ^a  

^a UNIVERSIDAD NACIONAL DE MISIONES   (Argentina)

Author keywords

Cancer; Diagnosis; Phosphotyrosine kinases; Phosphotyrosine phosphatases; Signaling pathway; Treatment

Indexed keywords

CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR; GROWTH FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE SHP 1; SOMATOSTATIN RECEPTOR;

APOPTOSIS; ARTICLE; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURVIVAL; DEPHOSPHORYLATION; HUMAN; NEOPLASM; NONHUMAN; PATENT; PHOSPHORYLATION; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PATENTS AS TOPIC; PHOSPHORYLATION; PROTEIN TYROSINE PHOSPHATASES; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 80054107304     PISSN: 18722156     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221511797636257     Document Type: Article

References (99)

1. Jia Z. Protein phosphatases: Structures and implications. Biochem Cell Biol 1997; 75: 17-26.
2. Wackerhage H, Ratkevicius A. Signal transduction pathways that regulate muscle growth. Essays Biochem 2008; 44: 99-108.
3. Blume-Jensen P, Hunter T. Oncogenic kinase signalling. Nature 2001; 411: 355-65.
4. Mayer BJ. Clues to the evolution of complex signaling machinery. PNAS 2008; 105: 9453-4.
5. Hunter T. The role of tyrosine phosphorylation in cell growth and disease. Harvey Lect 1998-1999; 94: 81-119.
6. Zapata PD, Colas B, López-Ruiz P, et al. Fosfotirosina fosfatasa SHP-1, somatostatina y cáncer de próstata. Actas Urol Esp 2004; 28: 269-85.
7. Zhang ZY. Mechanistic studies on protein tyrosine phosphatases. Prog Nucleic Acid Res Mol Biol 2003; 73: 171-220.
8. Graves JD, Krebs EG. Protein phosphorylation and signal transduction. Pharmacol Ther 1999; 82: 111-21.
9. Easty D, Gallagher W, Bennett DC. Protein tyrosine phosphatases, new targets for cancer therapy. Curr Cancer Drug Targets 2006; 6: 519-32.
10. Castaneda CA, Cortes-Funes H, Gomez HL, Ciruelos EM. The phosphatidyl inositol 3-kinase/AKT signaling pathway in breast cancer. Cancer Metastasis Rev 2010, 29:751-9.
11. Zeggari M, Esteve JP, Rauly I, et al. Co-purification of a protein tyrosine phosphatase with activated somatostatin receptors from rat pancreatic acinar membranes. Biochem J 1994; 303: 441-8.
12. Zhang ZY, Zhou B, Xie L. Modulation of protein kinase signaling by protein phosphatases and inhibitors. Pharmacol Ther 2002; 93: 307-17.
13. Tonks NK, Neel BG. Combinatorial control of the specificity of protein tyrosine phosphatases. Curr Opin Cell Biol 2001; 13: 182-95.
14. Li L, Dixon JE. Form, function, and regulation of protein tyrosine phosphatases and their involvement in human diseases. Semin Immunol 2000; 12: 75-84.
15. Barford D, Das AK, Egloff MP. The structure and mechanism of protein phosphatases: insights into catalysis and regulation. Annu Rev Biophys Biomol Struct 1998; 27: 133-64.
16. Doody KM, Bourdeau A, Tremblay ML. T-cell protein tyrosine phosphatase is a key regulator in immune cell signaling: lessons from the knockout mouse model and implications in human disease. Immunol Rev 2009; 228: 325-41.
17. Zhang ZY. Protein tyrosine phosphatases: prospects for therapeutics. Curr Opin Chem Biol 2001; 5: 416-23.
18. Mackinnon AC, Yan BC, Joseph LJ, Al-Ahmadie HA. Molecular biology underlying the clinical heterogeneity of prostate cancer: An update. Arch Pathol Lab Med 2009; 133: 1033-40.
19. Narod SA, Seth A, Nam R. Fusion in the ETS gene family and prostate cancer. Br J Cancer 2008; 99: 847-51.
20. Drewes G, Bouwmeester T. Global approaches to protein-protein interactions. Curr Opin Cell Biol 2003; 15: 199-205.
21. Kumar S, Zhou B, Liang F, Wang WQ, Huang Z, Zhang ZY. Activity- based probes for protein tyrosine phosphatases. Proc Natl Acad Sci USA 2004; 101: 7943-8.
22. Jiang ZX, Zhang ZY. Targeting PTPs with small molecule inhibitors in cancer treatment. Cancer Metastasis Rev 2008; 27: 263-72.
23. Bruecher-Encke B, Griffin JD, Neel BG, Lorenz U. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia 2001,15: 1424-32.
24. Esposito N, Izzo B, Kalebic T, Pane F, Quarantelli F. Method for optimizing the treatment of chronic myeloid leukemia with ABL tyrosine kinase inhibitors. WO2010054045, 2010.
25. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007; 22: 1251-67.
26. Balmanno K, Cook SJ. Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ 2009; 16: 368-77.
27. Tartaglia M, Gelb BD. Germ-line and somatic PTPN11 mutations in human disease. Eur J Med Genet 2005; 48: 81-96.
28. Matozaki T, Murata Y, Saito Y, Okazawa H, Ohnishi H. Protein tyrosine phosphatase SHP-2: a proto-oncogene product that promotes Ras activation. Cancer Sci 2009; 100: 1786-93.
29. Baron M, Davignon JL. Inhibition of IFN-gamma-induced STAT1 tyrosine phosphorylation by human CMV is mediated by SHP2. J Immunol 2008; 181: 5530-6.
30. Irandoust M, van den Berg TK, Kaspers GJ, Cloos J. Role of tyrosine phosphatase inhibitors in cancer treatment with emphasis on SH2 domain-containing tyrosine phosphatases (SHPs). Anticancer Agents Med Chem 2009; 9: 212-20.
31. Wu J, Lawrence NJ, Sebti SM, Lawrence HR. Indoline scaffold shp-2 inhibitors and method of treating cancer. WO2010121212, Wu, Jie,; Lawrence, Nicholas, James,; Sebti, Said M,; Lawrence, Harsha 2010.
32. Wu J, Lawrence NJ, Sebti SM, Lawrence HR. Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-117199 and analogs. WO2009135000, 2010.
33. Zapata PD, Ropero RM, Valencia AM, et al. Autocrine regulation of human prostate carcinoma cell proliferation by somatostatin (SRIF) through modulation of the tyrosine phosphatase SHP-1. J Endocr Metab 2002; 87: 915-26.
34. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010; 31: 169-88.
35. Lee Huai-C, Shane Guang-T, Wang Hsi-C, Lin R. Methods and compositions for treating disease or condition related to orexin receptor 1, orexin receptor 2, somatostatin receptor 2 or dopamine D2L receptor. WO2011057471, 2011.
36. Rivier JEF, Erchegyi J, Reubi JC, Maecke HR. Somatostatin receptor 2 antagonists. WO2009129311, 2010.
37. Buscail L, Tiraby G, Vernejoul F, Susini C, Drocourt D. Combination Products For Treating Cancer. US2010222418, 2010.
38. Pingda R, Yi L, Wilson TE, Liansheng L, Chan K. Benzoxazole kinase inhibitors and methods of use. US20100190749, 2010.
39. Doukas J, Mak CC, Dneprovskaia E, Noronha G. Kinase inhibitors and methods of use thereof. US7691858, 2010.
40. Dong Q, Paraselli BR, Scorah N, Wallace MB, Stafford JA. Kinase inhibitors. US20100190816, 2010.
41. Tauton J, Cohen M, Shokat K, Zhang C. Selective serine/threonine kinase inhibitors. US20100256171, 2010.
42. Eisenmann KM, VanBrocklin MW, Staffend NA, Kitchen SM, Koo HM. Mitogen-activated protein kinase pathwaydependent tumor-specific survival signaling in melanoma cells through inactivation of the proapoptotic protein bad. Cancer Res 2003; 63: 8330-7.
43. Shimamura A, Ballif BA, Richards SA, Blenis J. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol 2000; 10: 127-35.
44. Nguyen TL. Targeting RSK: an overview of small molecule inhibitors. Anticancer Agents Med Chem 2008; 8: 710-6.
45. Bhatia SN, von Maltzahn GA. Methods and systems for treatment and/or diagnosis. US20100260677, 2010.
46. Michl P, Downward J. Mechanisms of disease: PI3K/AKT signaling in gastrointestinal cancers. Z Gastroenterol 2005; 43: 1133-9.
47. Wickenden JA, Watson CJ. Key signaling nodes in mammary gland development and cancer. Signalling downstream of PI3 kinase in mammary epithelium: a play in 3 Akts. Breast Cancer Res 2010; 12: 202.
48. Lin H, Rouse MB, Seefeld MA, Xie R. Inhibitors of akt activity. US2011098221, 2011.
49. Bell MP, O'Dowd CR, Rountree JSS, Trevitt GP, Harrison T, Mcfarland MM. AKT/PKB inhibitors. WO2011055115, 2011.
50. Rouse MB, Seefeld MA. Inhibitors of akt activity. US2011092423, 2011.
51. Furuyama H, Goto Y, Kawanishi N, et al. Inhibitors of akt activity. US2011092511, 2011.
52. Seefeld MA, Rouse MB, Heerding DA. Inhibitors of AKT Activity. US2011071182, 2011.
53. Bencsik JR, Blake JF, Kallan NC, et al. Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors. US2011065716, 2011.
54. Banka A, Bencsik JR, Blake JF, et al. Pyrimidyl cyclopentanes as akt protein kinase inhibitors. US2011053959, 2011.
55. Chen Ching-S. PDK-1/AKT signaling inhibitors. US2011015242, 2011.
56. Liang J, Blake JF, Mitchell IS, et al. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor. MX2010007546, 2010.
57. Chen Q, Cui M, Hu B, et al. Inhibitors of akt activity. WO2010114780, 2010.
58. Fan W, Haxell TFN, Jenks MG, et al. Inhibitors of akt activity. WO2010104933, 2010.
59. Sanderson PE, Layton ME, Rodzinak KJ. Inhibitors of akt activity. WO2010104705, 2010.
60. Maier T, Beckers T, Baer T, et al. Fused imidazoles for cancer treatment. MX2010001745, 2010.
61. Armstrong DJ, Goto Y, Hashihayata T, et al. Inhibitors of akt activity. WO2010088177, 2010.
62. Bilodeau MT, Chua PC, Cosford NDP, Hoffman JM, Nagasawa JY. Inhibitors of akt activity. US2010075970, 2010.
63. Mitchell IS, Spencer KL, Stengel P, et al. AKT protein kinase inhibitors. US2010168123, 2010.
64. Layton ME, Hirai H, Kotani H. Combination cancer therapy with an akt inhibitor and other anticancer agents. WO2010101734, 2010.
65. Dennis PA, Hollander MC, Nicklaus M, Peach M, Chemler SR. Method of treating or preventing cancer. WO2011009059, 2011.
66. Pellecchia M. Selective inhibitors of akt and methods of using same. WO2010075443, 2010.
67. Korkola JE, Gray JW, Bayani N. PIK3CA mutation status and sash1 expression predicts synergy between lapatinib and an AKT inhibitor in HER2 positive breast cancer. WO2011060380, 2011.
68. Mahajan NP, Mahajan KN. AKT tyrosine 176 phosphorylation cancer biomarker. WO2010091354, 2010.
69. Yang SX, Swain SM. AKT phosphorylation at ser473 as an indicator for taxane-based chemotherapy. WO2010135671, 2010.
70. Muraca PJ. Anti-phospho-akt antibodies. US2010092473, 2010.
71. Cain RJ, Ridley AJ. Phosphoinositide 3-kinases in cell migration. Biol Cell 2009; 101 (1): 13-29.
72. Martelli AM, Cocco L, Capitani S, Miscia S, Papa S, Manzoli FA. Nuclear phosphatidylinositol 3, 4, 5-trisphosphate, phosphatidylinositol 3-kinase, Akt, and PTen: emerging key regulators of antiapoptotic signaling and carcinogenesis. Eur J Histochem 2007; 51 (1): 125-31.
73. Sutherlin DP, Castanedo G, Chuckowree I, Folkes A, Wan NC. Purine PI3K inhibitor compounds and methods of use. MX2010012583, 2010.
74. Muthuppalaniappan M, Viswanadha S, Babu G, Vakkalanka Swaroop KVS. Novel kinase modulators. US2011118257, 2011.
75. Nuss JM, Pecchi S, Renhowe PA. 2, 4, 6-trisubstituted pyrimidines as phosphotidylinositol (PI) 3-kinase inhibitors and their use in the treatment of cancer. EP2316831, 2011.
76. Hancox TC, Pegg NA, Beswick MC, et al. Thiazolopyrimidines and their use as inhibitors of phosphatidylinositol-3 kinase. US2011098270, 2011.
77. Belvin M, Chan IT, Friedman L, Hoeflich KP, Prescott J, Wallin J. Combinations of a pi3k inhibitor and a mek inhibitor. WO2011054620, 2011.
78. Taniyama D, Kano K, Okamoto K, Fujioka M, Mitsuoka Y. Heterocyclic compound having inhibitory activity on PI3K. US2011105457, 2011.
79. Dong Q, Gong X, Hirose M, Jin B, Zhou F. PI3K/M TOR inhibitors. EP2311842, 2011.
80. Hentemann M, Wood J, Scott W, Michels M, Campbell Ann-M, Bullion Ann-M, Rowley BR, Redman A. Substituted 2,3- dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis. US2011083984, 2011.
81. Liang C. PI3K (delta) selective inhibitors. WO2011041399, 2011. (Liang, Congxin) (Hentemann Martin,; Wood Jill,; Scott William,; Michels Martin,; Campbell Ann-Marie,; Bullion Ann- Marie,; Rowley Bruce R,; Redman Aniko) (Taniyama Daisuke,; Kano Kazuya,; Okamoto Kazuya,; Fujioka Masahiko,; Mitsu
82. Messersmith D, Aronov A, Lauffer DJ, Grillot Anne-L, Davies RJ. Pyrazole inhibitors of phosphatidylinositol 3-kinase. US2011081316, 2011.
83. Blaquiere N, Do S, Dudley D, et al. Benzoxazepin PI3K inhibitor compounds and methods of use. US2011076292, 2011.
84. Skinner MK. Cancer chemotherapy compositions comprising PI3K pathway modulators and triptolide. US2011045102, 2011.
85. Xing MM. Induction of thyroid iodide-handling gene expression in human cancers US2011038792, 2011.
86. Castanedo GM, Gunzner JL, Malesky K, et al. Thiazolopyrimidine pi3k inhibitor compounds and methods of use. US2011112085, 2011.
87. Bayliss T, Chuckowree I, Folkes A, et al. Phosphoinositide 3- kinase inhibitor compounds and methods of use. US2011097349, 2011.
88. Garcia-Echeverria C, Maira S-M. Combination of a phosphatidylinositol-3-kinase (pi3k) inhibitor and a mtor inhibitor. CA2736361, 2010.
89. Zhu B-Y, Olivero AG, Goldsmith R, et al. Benzopyran and benzoxepin PI3K inhibitor compounds and methods of use. MX2010010659, 2010. (Bing-Yan Zhu,; Alan G. Olivero,; Richard Goldsmith,; Tim Heffron,; Daniel P. Sutherlin,; Tracy Bayliss,; Aleksandr Kolesnikov,; Paul Goldsmith,; Steven Do,; Steven Staben,; Michael Siu,; Adrian Folkes,; Neil Pegg)
90. Murata T, Ebiike H, Ohwada J, Koyama K, Hong WS. Pyrrolopyrimidin derivative for use as pi3k inhibitor, and use thereof. MX2010008686, 2010.
91. Li Y-L, Metcalf BW, Combs A. Pyrimidinones as pi3k inhibitors. WO2011008487, 2011.
92. Lin H, Luengo JI, Rivero RA, Schulz MJ, Xie R, Zeng J. Thiazolopyrimidinone derivatives as pi3 kinase inhibitors. WO2010135504, 2010.
93. Dotson J, Heffron T, Olivero AG, et al. Pyrazolopyridine PI3K inhibitor compounds and methods of use WO2010059788, 2010.
94. Sadhu C, Dick K, Treiberg J, Sowell CG, Kesicki EA, Oliver A. Inhibitors of human phosphatidylinositol 3-kinase delta. US2010152211, 2010.
95. Fujioka M, Mitsumori S, Kugimiya A, Taniyama D. Ring-fused morpholine derivative having pi3k-inhibiting activity. WO2010027002, 2010.
96. Parsons DW, Wang T-L, Samuels Y, et al. PI3K pathway mutations in cancer. US2011059434, 2011.
97. Taranger-Charpin C. A method for predicting clinical outcome of patients with breast carcinoma. WO2011009908, 2011.
98. Chong ZZ, Maiese K. The Src homology 2 domain tyrosine phosphatases SHP-1 and SHP-2: diversified control of cell growth, inflammation, and injury. Histol Histopathol 2007; 22:1251-67.
99. Tiscornia MM, Riera MA, Lorenzati MA, Zapata PD. Phosphotyrosine phosphatases in cancer diagnostic and treatment. Rec Pat DNA Gene Sequences 2010, 4: 46-51.